Molecular classification of breast cancer
暂无分享,去创建一个
Peter T. Simpson | Sunil R. Lakhani | S. Lakhani | M. Cummings | P. Simpson | Margaret C. Cummings | Darina Vuong | B. Green | Darina Vuong | Benjamin Green
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] Jack Cuzick,et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Thompson,et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.
[4] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[5] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[6] William C Hahn,et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. , 2009, Cancer cell.
[7] P. Sorensen,et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.
[8] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[9] Karla Kerlikowske,et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.
[10] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[11] H. Schwarzenbach. Circulating nucleic acids as biomarkers in breast cancer , 2013, Breast Cancer Research.
[12] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[13] B. Shapiro,et al. Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.
[14] J. Reis-Filho,et al. Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.
[15] Emad A. Rakha,et al. Combinatorial biomarker expression in breast cancer , 2010, Breast Cancer Research and Treatment.
[16] W. McGuire,et al. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. , 1978, Endocrinology.
[17] V. Jordan,et al. The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] A. Ashworth,et al. Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components , 2009, The Journal of pathology.
[19] M. Fernö,et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels , 2004, Breast Cancer Research and Treatment.
[20] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[21] Robin L. Jones,et al. Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication , 2009, Journal of Clinical Pathology.
[22] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[23] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[24] M. Gilcrease,et al. Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients , 2008 .
[25] S. Devries,et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. , 2002, Human pathology.
[26] Jorge S. Reis-Filho,et al. Going with the Flow: From Circulating Tumor Cells to DNA , 2013, Science Translational Medicine.
[27] D. Easton,et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.
[28] I. Ellis,et al. Modern Classification of Breast Cancer: Should we Stick With Morphology or Convert to Molecular Profile Characteristics , 2011, Advances in anatomic pathology.
[29] G. Azabdaftari,et al. Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .
[30] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[31] Thomas J. Smith,et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[33] B. Kreike,et al. The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type , 2010, The Journal of pathology.
[34] Jorge S Reis-Filho,et al. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.
[35] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[36] Päivikki Kauraniemi,et al. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. , 2003, The American journal of pathology.
[37] P. O’Connell,et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.
[38] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[40] Ian O Ellis,et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[42] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[43] I. Ellis,et al. Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade? , 2013, Modern Pathology.
[44] A. Vincent-Salomon,et al. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum , 2009, Modern Pathology.
[45] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[46] Shu Ichihara,et al. Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.
[47] O. Dietze,et al. Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.
[48] A. Schäffer,et al. Tumorigenesis and Neoplastic Progression Single-Cell Genetic Analysis of Ductal Carcinoma in Situ and Invasive Breast Cancer Reveals Enormous Tumor Heterogeneity yet Conserved Genomic Imbalances and Gain of MYC during Progression , 2012 .
[49] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[50] G. Ball,et al. Reading the prognosis of the individual with breast cancer. , 2007, European journal of cancer.
[51] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[52] S. Devries,et al. Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ , 2004, Clinical Cancer Research.
[53] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[54] A. Ashworth,et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.
[55] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[56] D. Easton,et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.
[57] Nilanjan Chatterjee,et al. Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.
[58] Karla Kerlikowske,et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.
[59] S. Lakhani,et al. Molecular evolution of breast cancer , 2005, The Journal of pathology.
[60] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[61] Sunil R Lakhani,et al. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. , 2005, Pathology, research and practice.
[62] A. Goldhirsch,et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. , 2012, Clinical breast cancer.
[63] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[64] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[65] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[66] W. McGuire,et al. Specific progesterone receptors in human breast cancer , 1975, Steroids.
[67] M. Alaoui-Jamali,et al. Molecular insights on basal-like breast cancer , 2012, Breast Cancer Research and Treatment.
[68] P. Fortina,et al. Circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[69] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] J. Bergh,et al. Identification of molecular apocrine breast tumours by microarray analysis , 2005, Breast Cancer Research.
[71] A. Ashworth,et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.
[72] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[74] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[75] C. Poremba,et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.
[76] J. Polman,et al. ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.
[77] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[78] F. Bertucci,et al. A refined molecular taxonomy of breast cancer , 2011, Oncogene.
[79] V. Tsikitis,et al. Biology of Ductal Carcinoma in Situ Classification Based on Biologic Potential , 2006, American journal of clinical oncology.
[80] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] A. Ashworth,et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas , 2008, The Journal of pathology.
[82] R. Greil,et al. Circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[83] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] T. Sørlie,et al. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study , 2013, BMC Cancer.
[85] Daniel Pinkel,et al. Genomic microarrays in human genetic disease and cancer. , 2003, Human molecular genetics.
[86] Johan Staaf,et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] G. Parmigiani,et al. Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.
[88] Steven A. Roberts,et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.
[89] P. Stephens,et al. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. , 2014, The oncologist.
[90] J. Polman,et al. ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .
[91] Shu Ichihara,et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.
[92] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[93] R. Vierkant,et al. p16INK4a Expression and Breast Cancer Risk in Women with Atypical Hyperplasia , 2011, Cancer Prevention Research.
[94] G. Ball,et al. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers , 2013, British Journal of Cancer.
[95] L. Pusztai,et al. Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.
[96] Michael L. Gatza,et al. A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.
[97] 안성민. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2011 .
[98] Adrian V. Lee,et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. , 2005, Journal of the National Cancer Institute.
[99] P. Kauraniemi,et al. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.
[100] J. Thiery,et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[101] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.
[102] A. Vincent-Salomon,et al. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. , 2010, European journal of cancer.
[103] M. J. van de Vijver. Molecular tests as prognostic factors in breast cancer. , 2014, Virchows Archiv : an international journal of pathology.
[104] Kenny Q. Ye,et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.
[105] Jorge S. Reis-Filho,et al. Histological types of breast cancer: How special are they? , 2010, Molecular oncology.
[106] A. Molinolo,et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. , 2009, Endocrine-related cancer.
[107] G. Tse,et al. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters , 2004, Modern Pathology.
[108] H. Horlings,et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.
[109] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[110] Charles M. Perou,et al. Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.
[111] Charles M. Perou,et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.
[112] Funda Meric-Bernstam,et al. Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.
[113] Lajos Pusztai,et al. Molecular classification of breast cancer: limitations and potential. , 2006, The oncologist.